BUSINESSBLOOMBERG
Cancer Drugmaker Parabilis Seeks $475 Million in US IPO
Cancer drugmaker Parabilis is seeking $475 million through a US IPO. The article references an MRI scan depicting lung cancer in the left pulmonary lobe.
Related Signal
Adjacent reporting
- Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
- STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
- Antidepressant Drugmaker Seaport Seeks $212.4 Million in US IPO
- STAT+: Medicare’s miss on Alzheimer’s drug spending
- Malaysia’s Largest Pharma Chain Big Caring Is Said to Seek $750 Million in IPO
- Chinese drug reduces lung cancer death risk by 34% in trial